Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc., a pioneering biotechnology company headquartered in the United States, focuses on developing innovative RNA-based therapies for severe genetic diseases. Founded in 2018, Stoke has quickly established itself in the biopharmaceutical industry, particularly in the field of genetic medicine. The company is renowned for its proprietary TANGO™ platform, which uniquely enhances the expression of specific genes to address the underlying causes of diseases. This cutting-edge approach sets Stoke apart in a competitive market, positioning it as a leader in the development of treatments for conditions such as epilepsy and other neurological disorders. With a commitment to advancing genetic therapies, Stoke Therapeutics continues to achieve significant milestones, solidifying its reputation as a key player in the biotechnology landscape.
DitchCarbon Score
How does Stoke Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Stoke Therapeutics, Inc.'s score of 36 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Stoke Therapeutics, Inc.'s reported carbon emissions
Stoke Therapeutics, Inc., headquartered in the United States, has set ambitious climate commitments aimed at significantly reducing its carbon emissions. Although specific emissions data for the most recent year is not available, the company has established science-based targets for its greenhouse gas emissions. Stoke Therapeutics has committed to reducing its Scope 1 and Scope 2 emissions by 42% by 2030, using 2023 as the base year. Furthermore, the company aims for a substantial long-term reduction of 90% in both Scope 1 and Scope 2 emissions by 2050. These targets are aligned with the 1.5°C climate goal, ensuring that their operations contribute to global efforts to mitigate climate change. In addition to its direct emissions, Stoke Therapeutics is also focused on measuring and reducing its Scope 3 emissions, which encompass indirect emissions from its value chain. The company has pledged to achieve net-zero emissions across all scopes by 2050, reinforcing its commitment to sustainability and environmental responsibility. These targets have been validated by the Science Based Targets initiative (SBTi), reflecting a robust approach to climate action within the professional services sector. As Stoke Therapeutics progresses towards these goals, it demonstrates a proactive stance in addressing climate change and reducing its carbon footprint.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Stoke Therapeutics, Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
